Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US10322111B2 · kind B2 · utility
0Cited by
30References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2016 |
| Grant date | Jun 18, 2019 |
| Priority date | — |
| Expiry date | Feb 8, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.